CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
bevacizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00670982
NCT00670982Phase 2Completed
CompareCT.gov

Phase 2 Study of Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer

Harold J. Burstein, MD, PhD·interventional·Posted May 2, 2008·Updated May 13, 2013

In Brief

A Phase 2 clinical trial evaluating bevacizumab, vinorelbine, and 1 other intervention for Breast Cancer. Completed, enrolled 29 participants across 7 sites.

Detailed Summary

The purpose of this research study is to determine the effects of the combination of bevacizumab, vinorelbine, and trastuzumab on participants and their cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Genentech, Inc., New Hampshire Oncology-Hematology PA, Lowell General Hospital, Hartford Hospital

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2, 2008
Enrollment StartMay 1, 2008
Primary CompletionDec 1, 2011
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 18.2 years ago

Interventions

bevacizumabdrug

Given intravenously every 2 weeks

vinorelbinedrug

Given intravenously once a week

trastuzumabdrug

Given intravenously once a week